(Q39373956)

11 September 2017

title

Molecular subtyping of brain metastases and implications for therapy (English)

1 reference

11 September 2017

1 reference

Jaclyn J Renfrow

1

1 reference

11 September 2017

Glenn J Lesser

series ordinal

2

1 reference

11 September 2017

publication date

1 December 2013

1 reference

Current Treatment Options in Oncology

11 September 2017

published in

1 reference

11 September 2017

volume

14

1 reference

11 September 2017

issue

4

1 reference

11 September 2017

page(s)

514-527

1 reference

The management of brain metastases

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Roentgen-ray therapy of cerebral metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Radiosurgery to the surgical cavity as adjuvant therapy for resected brain metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

A randomized trial of surgery in the treatment of single metastases to the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Surgical treatment of multiple brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Radiation therapy in the management of brain metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Multimodality management of non-small cell lung cancer patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Vemurafenib for melanoma metastases to the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Melanoma brain metastases and vemurafenib: need for further investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-013-0248-2

Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment

21 January 2018

1 reference

12 December 2020

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases

1 reference

12 December 2020

Prognostic factors for survival in melanoma patients with brain metastases

1 reference

12 December 2020

Surgical treatment for brain metastases: prognostic factors and survival in 177 patients

1 reference

12 December 2020

1 reference

12 December 2020

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

1 reference

12 December 2020

Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases

1 reference

12 December 2020

The palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology group

1 reference

12 December 2020

Patterned distribution of metastases from malignant melanoma in humans.

1 reference

12 December 2020

Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques.

1 reference

12 December 2020

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

1 reference

12 December 2020

Management of central nervous system metastases

1 reference

12 December 2020

Intracerebral metastases in solid-tumor patients: Natural history and results of treatment

1 reference

12 December 2020

10.1007/S11864-013-0248-2

Identifiers

DOI

1 reference

11 September 2017

1 reference